No recent analyst price targets found for ELOX.
Latest News for ELOX
Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq
ARLINGTON, Mass., June 8, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) ("Eloxx" and the "Company"), a clinical-stage biopharmaceutical company developing novel, small molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations to enable the production of full-length proteins, today announced the pricing of a public…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ELOX.
U.S. House Trading
No House trades found for ELOX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.